Manufacturing Biotherapeutics to GMP standard for clinical trials can be one of the most difficult hurdles to overcome. Below are a number of facilities capable of manufacturing clinical and pre-clinical grade therapeutics including plasmid, oligonucleotides and viral vectors. There are also a selection of facilities capable of conducting the range of tests necessary to meet safety standards.
Viral Vector Production Unit
CRISPR-Cas9 genome editing - molecular scissors a bit too sharp?
Grégoire Cullot received the ESGCT-sponsored prize for best oral presentation at the Société Française de Thérapie Cellulaire et Génique (SFTCG) Thematic Day on Viral Vectors, which took place on 17 May 2019 in Paris. Read about his winning presentation here!
Dgkk as a new therapeutic target in the Fmr1-KO murine model of Fragile X
Karima Habbas received the ESGCT-sponsored prize for best poster at the Société Française de Thérapie Cellulaire et Génique (SFTCG) Thematic Day on Viral Vectors, which took place on 17 May 2019 in Paris. Read about her winning presentation here!
Hellenic Society of Gene Therapy and Regenerative Medicine - 4th Congress
Spring School 2019 Report
Copyright ©2016 European Society of Gene and Cell Therapy | Website by OFEC